Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
Eli Lilly and Company, Basingstoke, United Kingdom.
Clin Ther. 2019 Aug;41(8):1622-1630. doi: 10.1016/j.clinthera.2019.05.010. Epub 2019 Jun 1.
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting.
最近，两种二肽基肽酶-4（DPP-4）抑制剂，西格列汀和沙格列汀，调整了剂量规格，从肌酐清除率改为肾小球滤过率，更常用于常规实验室检测。本横断面研究使用英国普通实践的数据，调查了所有需要剂量调整的 DPP-4 抑制剂起始治疗以及剂量选择。结果表明，34%服用非利拉那汀 DPP-4 抑制剂的患者，其剂量高于产品特性摘要中规定的剂量，11%患者剂量低于规定剂量。这与之前研究中发现的 DPP-4 抑制剂与产品特性摘要不符的情况一致，尽管其与常规报告的兼容性有所改善。
